New hope for advanced liver cancer: Triple-Drug combo enters early testing
NCT ID NCT07557251
First seen May 06, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-stage study tests a new experimental drug (BRII-5395) combined with two approved cancer drugs (sintilimab and bevacizumab) in 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while also looking for signs that the combination shrinks tumors or slows the disease. Participants must have already tried at least one prior cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HBV-RELATED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Contact
Conditions
Explore the condition pages connected to this study.